New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: Synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 2, 2009, Pages 675-689

  Gökhan Kelekçi, Nesrin ^a   Koyunoǧlu, Semra ^a   Yabanoǧlu, Samiye ^a   Yelekçi, Kemal ^b   Özgen, Özen ^a   Uçar, Gülberk ^a   Erol, Kevser ^c   Kendi, Engin ^a   Yeşilada, Akgül ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b KADIR HAS UNIVERSITY   (Turkey)

^c ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

2 Pyrazoline; Antidepressant anxiogenic activities; Crystallographic model; Docking; MAO A MAO B inhibition

Indexed keywords

2 (1,3' DIPHENYL 2' PROPENYLIDENE)HYDRAZINE 3 METHYL 4(3H) QUINAZOLINONE; 2 (3,5' DIPHENYL 2' PYRAZOLINE 1 YL) 3 METHYL 4(3H) QUINAZOLINONE; 2 [1' PHENYL 3' (3 CHLOROPHENYL) 2' PROPENYLIDENE]HYDRAZINE 3 METHYL 4(3H) QUINAZOLINONE; 2 [1' PHENYL 3' (4 BROMOPHENYL) 2' PROPENYLIDENE]HYDRAZINE 3 METHYL 4(3H) QUINAZOLINONE; 2 [1' PHENYL 3' (4 METHOXYPHENYL) 2' PROPENYLIDENE]HYDRAZINE 3 METHYL 4(3H) QUINAZOLINONE; 2 [1' PHENYL 3' (4 METHYLPHENYL) 2' PROPENYLIDENE]HYDRAZINE 3 METHYL 4(3H) QUINAZOLINONE; 2 [3 PHENYL 5' (3 CHLOROPHENYL) 2' PYRAZOLIN 1 YL] 3 METHYL 4(3H) QUINAZOLINONE; 2 [3 PHENYL 5' (4 BROMOPHENYL) 2' PYRAZOLIN 1 YL] 3 METHYL 4(3H) QUINAZOLINONE; 2 [3 PHENYL 5' (4 CHLOROPHENYL) 2' PYRAZOLIN 1 YL] 3 METHYL 4(3H) QUINAZOLINONE; 2 [3 PHENYL 5' (4 METHOXYPHENYL) 2' PYRAZOLIN 1 YL] 3 METHYL 4(3H) QUINAZOLINONE; 2 [3 PHENYL 5' (4 METHYLPHENYL) 2' PYRAZOLIN 1 YL] 3 METHYL 4(3H) QUINAZOLINONE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTIDEPRESSANT AGENT; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PYRAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CHROMATOGRAPHY; CONTROLLED STUDY; CRYSTALLOGRAPHY; DRUG ACTIVITY; DRUG BINDING SITE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HYDROGEN BOND; MOLECULAR DOCKING; NONHUMAN; RAT; TRANQUILIZING ACTIVITY; X RAY CRYSTALLOGRAPHY;

BINDING SITES; FLAVIN-ADENINE DINUCLEOTIDE; HYDROGEN BONDING; HYDROPHOBICITY; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PYRAZOLES; QUINAZOLINONES;

EID: 58549107997     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.11.068     Document Type: Article

References (80)

1. Youdim M.B.H., Edmonson D., and Tipton K.F. Nat. Rev. Neurosci. 7 (2006) 295
2. Coutts R.T., Baker G.B., and Danielson T.J. New Developments in Monoamine Oxidase Inhibitors. In: Gorrod J.W., Gibson G.G., and Mitchard M. (Eds). Developments of Drugs and Modern Medicines. Part I. Drug Design (1986), Ellis Horwood Ltd, Chichester 40
3. Kalgutkar A.S., and Castagnoli Jr. N. Med. Res. Rev. 15 (1995) 325
4. Johston J.P. Biochem. Pharmacol. 17 (1968) 1285
5. Knoll J., and Magyar K. Adv. Biochem. Psychophys. 5 (1972) 393
6. O'Carroll A., Fowler C.J., Phillips J.P., Tobbia I., and Tipton K.F.N.-S. Arch. Pharmacol. 322 (1983) 198
7. Rudorfer M.V., and Potter W.Z. Drugs 37 (1989) 713
8. Pacher P., Kohegyi E., Keckemeti V., and Furst S. Curr. Med. Chem. 8 (2001) 89
9. Pacher P., and Keckemeti V. Curr. Med. Chem. 11 (2004) 925
10. Wouters J. Curr. Med. Chem. 5 (1998) 137
11. Carreiras M.C., and Marco J.L. Curr. Pharm. Des. 10 (2004) 367
12. Binda C., Newton-Vinson P., Hubálek F., Edmondson D.E., and Mattevi A. Nat. Struct. Biol. 9 (2002) 22
13. Edmondson D.E., Binda C., and Mattevi A. Neurotoxicology 25 (2004) 63
14. De Colibus L., Li M., Binda C., Lustig A., Edmondson D.E., and Mattevi A. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 12684
15. Hubálek F., Binda C., Khalil A., Li M., Mattevi A., Castagnoli N., and Edmondson D.E. J. Biol. Chem. 280 (2005) 15761
16. Cesura M.A., and Pletscher A. Prog. Drug Res. 38 (1992) 171
17. Tipton K.F. Biochem. J. 128 (1972) 913
18. Mc Kenna K.F., Baker G.B., and Coutta R.T.N.-S. Arch. Pharmacol. 343 (1991) 478
19. Yamada N., Takahashi S., Todd K.G., Baker G.B., and Paetsch P.R. J. Pharm. Sci. 82 (1993) 934
20. Parmar S.S., Pandey B.R., Dwivedi C., and Harbison R.D. J. Pharm. Sci. 63 (1974) 1152
21. Soni N., Pande K., Kalsi R., Gupta T.K., Parmar S.S., and Barthwal J.P. Res. Commun. Chem. Path. 56 (1987) 129
22. Manna F., Chimenti F., Bolasco A., Bizzarri B., Befani O., Pietrangeli P., Mondovi B., and Turini P.J. Enzyme Inhib. 13 (1998) 207
23. Manna F., Chimenti F., Bolasco A., Secci D., Bizzarri B., Befani O., Turini P., Mondovi B., Alcaro S., and Tafi A. Bioorg. Med. Chem. Lett. 12 (2002) 3629
24. Gökhan N., Yeşilada A., Uçar G., Erol K., and Bilgin A.A. Arch. Pharm. 336 (2003) 362
25. Chimenti F., Bolasco A., Manna F., Secci D., Chimenti P., Befani O., Turini P., Giovannini V., Mondovi B., Cirilli R., and La Torre F. J. Med. Chem. 47 (2004) 2071
26. Chimenti F., Maccioni E., Secci D., Bolasco A., Chimenti P., Granese A., Befani O., Turini P., Alcaro S., Ortuso F., Cirilli R., La Torre F., Cardia M.C., and Distinto S. J. Med. Chem. 48 (2005) 7113
27. Gökhan Kelekçi N., Yabanoǧlu S., Küpeli E., Salgi{dotless}n Gökşen U., Özgen O., Uçar G., Yeşilada E., Kendi E., Yeşilada A., and Bilgin A.A. Bioorg. Med. Chem. 15 (2007) 5775
28. Yeşilada A., Gökhan N., Özer I., Vural K., and Erol K. Farmaco 51 (1996) 775
29. Uçar G., Gökhan N., Yeşilada A., Yabanoǧlu S., and Bilgin A.A. Hacettepe Univ. J. Fac. Pharm. 25 (2005) 23
30. Yabanoǧlu S., Uçar G., Gökhan N., Salgi{dotless}n U., Yeşilada A., and Bilgin A.A. J. Neural. Transm. 114 (2007) 769
31. Uçar G., Gökhan N., Yeşilada A., and Bilgin A.A. Neurosci. Lett. 382 (2005) 327
32. Gupta R.C., Saxena A.K., Shanker K., and Kishor K. Indian J. Pharm. 39 (1977) 20
33. Mi{dotless}sra R.S., Chaudhari A., Chaturvedi A.K., Parmar S.S., and Sastry V.R. Pharmacol. Res. Commun. 9 (1977) 437
34. Srivastava V.K., Satsangi R.K., Kumar P., and Kishor K. J. Physiol. Pharmacol. 24 (1980) 361
35. Lata A., Satsangi R.K., Srivastava V.K., and Kishor K. Arzneimittel-Forsch. 32 (1982) 24
36. Shrimali M., Kalsi R., Dixit K.S., and Barthwal J.P. Arzneimittel-Forsch. 41 (1991) 514
37. Sheldrick, G. M. SHELXL-97. Program for Crystal Structure Refinement, University of Göttingen, Germany, 1997.
38. Sheldrick, G. M. SHELXS-97. Program for Crystal Structure Solution, University of Göttingen, Germany, 1997.
39. North A.C.T., Phillips D.C., and Mathews F.S. Acta Crystallogr. A24 (1968) 351
40. Farrugia L.J. J. Appl. Crystallogr. 30 (1997) 565
41. Ozgen O., Koyunoglu S., Kendi E., and Yesilada A. Struct. Chem. 16 (2005) 61
42. Krishna R., Velmurugan D., Shanmuga S.M., and Raghunathan R. Acta Crystallogr. C55 (1999) 1676
43. Isi{dotless}k K., Koysal Y., Ozdemir Z., and Bilgin A.A. Acta Crystallogr. E62 (2006) o491
44. Porsolt R.D., Anton G., Blavet N., and Jalfre M. Eur. J. Pharmacol. 47 (1978) 379
45. Pellow S., Chopin P., File S.E., and Briley M. J. Neurosci. Meth. 14 (1985) 149
46. Laux G., Volz H.P., and Moller H.J. CNS Drugs 3 (1995) 145
47. Thase M.E., Trivedi M.H., and Rush A.J. Neuropsychopharmacology 12 (1995) 185
48. Sunal R., Gümüşel B., and Kayaalp S.O. Pharmacol. Biochem. Behav. 49 (1994) 891
49. Buller R. Clin. Neuropharmacol. 18 (1995) S38
50. Priest R.G., Gimbrett R., Roberts W., and Steinert J. Acta Psychiat. Scand. 91 (1995) 40
51. Paslawski T., Treit D., Baker G.B., George M., and Coutts R.T. Psychopharmacology 127 (1996) 19
52. Lecci A., Borsini F., Volterra G., and Meli A. Psychopharmacology 101 (1990) 255
53. DeAngelis L. Biol. Psychiatry 42 (1997) 14
54. Caille D., Bergis O.E., Fankhauser C., Gardes A., Adam R., Charieras T., Grosset A., Rovei V., and Jarreau F.X. J. Pharmacol. Exp. Ther. 277 (1996) 265
55. Griebel G., Perrault G., and Sanger D.J. Psychopharmacology 131 (1997) 180
56. Butler K., and Partridge M.W. J. Chem. Soc. (1959) 1512
57. Fathalla W., Čajan M., and Pazdera P. Molecules 6 (2001) 557
58. Mehra H.S. J. Indian Chem. Soc. 45 (1968) 178
59. Yeşilada A., Koyunuǧlu S., Saygi{dotless}li{dotless} N., Küpeli E., Yeşilada E., Bedir E., and Khan I. Arch. Pharm. Pharm. Med. Chem. 337 (2004) 96
60. Holt A., Sharman D.F., Baker G.B., and Pelcic M.M. Anal. Biochem. 244 (1997) 384
61. Bradford M.M. Anal. Biochem. 72 (1976) 248
62. Binda C., Hubalek F., Li M., Edmondson D.E., and Mattevi A. FEBS Lett. 564 (2004) 225
63. Binda C., Hubalek F., Li M., Herzig Y., Sterling J., Edmondson D.E., and Mattevi A. J. Med. Chem. 47 (2004) 1767
64. Binda C., Newton-Vinson P., Hublek F., Edmondson D.E., and Mattevi A. Nat. Struct. Biol. 9 (2002) 22
65. De Colibus L., Min L., Binda C., Lustig A., Edmondson D.E., and Mattevi A. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 12684
66. Berendsen H.J.C., Van der Spoel D., and Van Drunen R. Comput. Phys. Commun. 91 (1995) 56
67. Lindahl E., Hess B., and Van der Spoel D. J. Mol. Model. 7 (2001) 306
68. Michel F., and Saner P. J. Mol. Graph. Model. 17 (1999) 57
69. Gasteiger J., and Marsili M. Tetrahedron 36 (1980) 3219
70. Wavefunction, Inc., 18401 von Karman Avenue, Suite 370, Spartan'02, Irvine, CA 92612, USA.
71. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. J. Comput. Chem. 19 (1998) 1639
72. Huey R., Morris G.M., Olson A.J., and Goodsell D.S. J. Comput. Chem. 28 (2007) 1145
73. Toprakçi M., and Yelekci K. Bioorg. Med. Chem. Lett. 15 (2005) 4438
74. Yelekci K., Karahan O., and Toprakci M. J. Neural. Transm. 114 (2007) 725
75. Humphrey W., Dalke A., and Schulten K. J. Mol. Graph. 14 (1996) 33
76. Lister R.G. Psychopharmacology 92 (1987) 10
77. Porsolt R.D., Bertin A., and Jalfre M. Arch. Int. Pharmacod. T. 229 (1977) 327
78. Lister R.G. Psychopharmacology 92 (1987) 180
79. Pellow S., Chopin P., File S.E., and Briley M.J. Neurosci. Methods 14 (1985) 149
80. Porsolt R.D., Anton G., Blavet N., and Jalfre M. Eur. J. Pharmacol. 47 (1978) 379